What it sells
AI Virtual Cell foundation models (OCOO) plus automated cell experiments to predict cellular responses to genetic, chemical and environmental perturbations.
Business model breakdown
Buyer: who owns the budget?
UnverifiedHead of discovery / R&D at pharma and biotech companies.
Trigger: what makes them buy now?
UnverifiedPharma and biotech teams needing faster disease-mechanism research, target discovery and drug screening than wet-lab-only methods.
Workflow: what inputs become what output?
Computational prediction, then in-vitro validation, then model iteration in a closed loop supporting target discovery and drug screening.
Economics: what it saves and how it charges
UnverifiedNot stated; likely research collaboration or model/platform service fees for drug discovery partners.
Distribution: how it reaches customers
Incubated by XtalPi (2228.HK) in Beijing; partnership and contact-led (site has Contact page only).
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-06-01 | Angel | CNY tens of millions | — | wap.eastmoney.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-13.